Gaining steam in PD-1/L1 race, Roche reports positive PhIII OS data on Tecentriq combo in NSCLC
Roche trotted out some early OS data Monday morning from its combo study of Tecentriq in lung cancer, reporting that the combo met its co-primary endpoint and helped patients live longer.
The data will back up the company’s upcoming bid for approval of the drug combo as a front-line therapy, making Roche a stronger contender among rivals Bristol-Myers Squibb and Merck as the PD-1/L1 market leader war wages on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.